Skip to Main Content

Paper Details

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study.
Int J Cancer
21
2021
Author NameAffiliation
Alexandra DrakakiUniversity of California Los Angeles (university of california los angeles)
  • 1 - 1

Datasets

Release 1.2